This generates oxidative stress and apoptosis of myocytes and impairs angiogenesis, leading to significant cardiovascular diseases.19,20,21,22 Clinical data document a reduction in LVEF under BRAF and MEK inhibitors in 5% to 11% of all patients, while arterial hypertension occurred in 10% to 15% of patients.10,17 Although QTc interval prolongation is denoted as a potential CVAE, several studies reported no association of BRAF and MEK inhibitor therapy with QTc intervals.10,17 Therefore, questions remain about whether this is a salient CVAE. The gene discussed is MAP2K7; the disease is cardiovascular disorder.